Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · Real-Time Price · USD
2.550
-0.030 (-1.16%)
At close: Nov 22, 2024, 4:00 PM
2.630
+0.080 (3.14%)
After-hours: Nov 22, 2024, 6:10 PM EST
Leap Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Leap Therapeutics stock have an average target of 8.63, with a low estimate of 5.50 and a high estimate of 12. The average target predicts an increase of 238.43% from the current stock price of 2.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LPTX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.5 | Strong Buy | Reiterates | $5.5 | +115.69% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.5 | Strong Buy | Reiterates | $5.5 | +115.69% | Aug 13, 2024 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +213.73% | Jun 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $5.5 | Strong Buy | Maintains | $7 → $5.5 | +115.69% | May 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +174.51% | Mar 19, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.84
from -3.98
EPS Next Year
-1.27
from -1.84
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 6.3M | ||
| Avg | n/a | n/a | 1.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.76 | -0.97 | -1.00 | ||
| Avg | -1.84 | -1.27 | -1.25 | ||
| Low | -1.90 | -1.53 | -1.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.